Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry.

ABSTRACT:

Background

Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF.

Objectives

To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients.

Design

Retrospective observational study.

Methods

Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially).

Results

Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 4

SUBMITTER: Calafat M 

PROVIDER: S-EPMC10771049 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature